Leverkusen (dpa -Afx) – Bayer did better than expected thanks to the pharmaceutical business than expected thanks to the pharmaceutical business. Due to a negative exchange rate effects, CEO Bill Anderson had to reduce the annual outlook in the tendency, which are available for exchange rate effects adjusted group forecasts for 2025. Bayer in the pharmaceutical division is now expecting an operational profit margin (adjusted EBITDA margin) in the upper area of the forecast corridor.
In the past first quarter, Group sales kept almost at the level of the same period of the same period last year at 13.7 billion euros. The result, which was adjusted for special effects before interest, taxes and depreciation (EBITDA), decreased by a little more than seven percent to just under 4.1 million euros. This means that the company cut off better than analysts expected it before. The bottom line is a surplus of 1.3 billion euros and thus a good third less than a year ago.
For 2025, Bayer – Effects from Exchange Change Changes excluded – is aiming for sales of 45 to 47 billion euros. On this basis, adjusted EBITDA is to continue to reach 9.3 to 9.8 billion euros. Including currency effects, an operational profit of 9.2 to 9.7 billion euros is targeted, which is 100 million euros less than before at the upper and lower end of the range.
Selected leverage products on Bayer
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Bayer
The lever must be between 2 and 20
Advertising